Marc Matrana, MD, FACP, MS
- Sr Physician-Medical Director, Southshore Region
- 1514 Jefferson Hwy, New Orleans, LA, 70121
For additional information or to make an appointment, click here.
Overview
Overview
- Dr. Marc Matrana is a ninth-generation native of the New Orleans region. He received his bachelor's and master's degrees in human genetics from Tulane University. He received his medical degree from the LSU School of Medicine in New Orleans. Dr. Matrana completed his internship and residency in internal medicine at Ochsner Medical Center where he served as Chief Medical Resident. He completed training in hematology and medical oncology at MD Anderson Cancer Center in Houston where he received numerous awards and served as both Chief Fellow for Resident Education and overall Chief Fellow. Dr. Matrana's clinical practice at Ochsner focuses on treating patients with cancers of the genitourinary tract as well as lung cancer, gastrointestinal cancer, and other malignancies and hematologic diseases. He has conducted much ground-breaking research and authored numerous peer-reviewed articles, chapters, and other publications in the field of genitourinary medical oncology. Dr. Matrana has spoken at conferences around the world on kidney cancer and is a recognized expert in the field. In addition to research and patient care, he is an active medical educator serving in leadership positions with local medical schools, including the University of Queensland School of Medicine/Ochsner Clinical School and the Ochsner Medical Oncology Fellowship Program.
Publications
Selected publications
-
2023Early real-world (RW) experience with a multi-cancer early detection (MCED) test.. Journal of Clinical Oncology. 41.
-
2023A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.. Journal of Clinical Oncology. 41:361-361.
-
2022A Ph-Ib study of TRK-950 combined with anti-cancer treatment regimens in patients with advanced solid tumors. European Journal of Cancer. 174:S32-S33.
-
2022Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma. European Journal of Cancer. 172:191-198.
-
2022Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clinical Genitourinary Cancer. 20:285-295.
-
2022PREVALENCE OF GENETIC TESTING AND MUTATIONS IN METASTATIC PROSTATE CANCER IN REAL-WORLD PRACTICE AT A SINGLE INSTITUTION. Journal of Investigative Medicine. 70:673-674.
-
2021Combination Therapy With Bortezomib in Renal Medullary Carcinoma: A Case Series. Clinical Genitourinary Cancer. 19:E395-E400.
-
2021Artificial Neural Networks as a Way to Predict Future Kidney Cancer Incidence in the United States. Clinical Genitourinary Cancer. 19:E84-E91.
-
2020A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies. Annals of Oncology. 31:S462-S463.
-
2020Immune checkpoint inhibitor use in cancer patients with a pre-existing history of autoimmune disorders. Journal of Clinical Oncology. 38.
-
2020Precision Medicine and the Institutional Review Board: Ethics and the Genome. The Ochsner Journal. 20:98-103.
-
2020Prostate cancer and COVID-19: Impact of hormonal therapy on severe outcomes.. Clinical Cancer Research. 26.
-
2020Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Abdominal Radiology. 45:1872-1882.
-
2019A Phase II Trial of Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Neuroendocrine Carcinoma. Journal of Thoracic Oncology. 14:S813-S814.
-
2019Chemotherapy Toxicity Confirms Diagnosis of Urachal Carcinoma. Clinical Genitourinary Cancer. 17:E913-E915.
-
2019Immunotherapy adverse events predict treatment response. Journal for ImmunoTherapy of Cancer. 7.
-
2019NET-001: A Phase II Study of ABI-009 in Metastatic Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System. Journal of Thoracic Oncology. 14:S1023-S1023.
-
2019No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment.. Journal of Clinical Oncology. 37.
-
2019Preliminary results of a Phase 1 trial with a personalized neoantigen vaccine (ADXS-NEO) in advanced and refractory cancer patients. Journal for ImmunoTherapy of Cancer. 7.
-
2019Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers. Journal of Thoracic Oncology. 14:S6-S7.
-
2019SMOKING HISTORY AND PD-1/PDL-1 PATHWAY BLOCKADE: PREDICTING RESPONSE TO TREATMENT IN METASTATIC CANCER. Journal of Investigative Medicine. 67:594-594.
-
2019SMOKING HISTORY AND PD-1/PDL-1 PATHWAY BLOCKADE: PREDICTING RESPONSE TO TREATMENT IN METASTATIC CANCER. Journal of Investigative Medicine. 67:569-569.
-
2019Smoking history and PD-1/PDL-1 pathway blockade: Predicting response to treatment in metastatic cancer.. Journal of Clinical Oncology. 37.
-
2018CHEMOTHERAPY TOXICITY CONFIRMS DIAGNOSIS OF URACHAL CARCINOMA. Journal of Investigative Medicine. 66:453-453.
-
2017ABOUND.PS2: Safety and Efficacy of Nab-Paclitaxel-Based Therapy in Patients with NSCLC and ECOG PS 2. Journal of Thoracic Oncology. 12:S2073-S2073.
-
2017Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy. American Journal of Roentgenology. 209:1278-1284.
-
2017Building a Phase 1 Cancer Research Program: Lessons Learned and Progress Made. The Ochsner Journal. 17:319-321.
-
2017Longitudinal Assessment of Performance Status (PS) in Patients with NSCLC and ECOG PS 2 on Nab-Paclitaxele-Based Therapy. Journal of Thoracic Oncology. 12:S2073-S2074.
-
2017
-
2017Primary Undifferentiated Pleomorphic Sarcoma of the Penis. The Ochsner Journal. 17:434-437.
-
2016
-
2016ABOUND.PS2 Interim Safety Results: nab-Paclitaxel/Carboplatin Followed by nab-Paclitaxel in NSCLC Patients with ECOG PS of 2. Journal of Thoracic Oncology. 11:S274-S274.
-
2016An Overview of Emerging Immunotargets of Genitourinary Tumors. Current Drug Targets. 17:750-756.
-
2016Emerging Immunotargets and Immunotherapies in Prostate Cancer. Current Drug Targets. 17:777-782.
-
2016Metastatic Prostate Cancer 35 Years After Sex Reassignment Surgery. Clinical Genitourinary Cancer. 14:E207-E209.
-
2016Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International. 117:761-765.
-
2016Treating renal cell carcinoma in young adults: challenges and solutions. Clinical Oncology in Adolescents and Young Adults. 6:31-38.
-
2016VERY LATE RELAPSE METASTATIC RENAL CELL CARCINOMA: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH A DISEASE FREE INTERVAL OF GREATER THAN 10 YEARS. Journal of Investigative Medicine. 64:705-706.
-
2015Adenosquamous carcinoma of the lung: a single institution experience in the era of molecular testing.. Journal of Clinical Oncology. 33.
-
2015BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics. 15:1201-1210.
-
2015In vitro synergistic cellular proliferation inhibition in pancreatic cancer cells Su86 and Mia-PaCa-2 with fluvastatin and nab-paclitaxel.. Journal of Clinical Oncology. 33.
-
2015In-vitro synergistic cellular proliferation inhibition in pancreatic cancer cells Su86 and Mia-PaCa-2 with fluvastatin and nab-paclitaxel.. Journal of Clinical Oncology. 33.
-
2015Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies: A single-institution experience.. Journal of Clinical Oncology. 33.
-
2015nab-Paclitaxel/Carboplatin Followed By nab-Paclitaxel for NSCLC PS 2 (ABOUND.PS2). Journal of Thoracic Oncology. 10:S553-S553.
-
2014Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience. Clinical Genitourinary Cancer. 12:348-353.
-
2014Outcomes of patients (pts) with metastatic non-clear-cell renal cell carcinoma (nccRCC) treated with pazopanib. Journal of Clinical Oncology. 32.
-
2014Outcomes of patients with late relapse metastatic renal cell carcinoma treated with targeted therapies.. Journal of Clinical Oncology. 32.
-
2014Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. Journal of Clinical Oncology. 32.
-
2014Renal Medullary Carcinoma: A Case Report and Brief Review of the Literature. The Ochsner Journal. 14:270-275.
-
2009Vitamin Deficiency After Gastric Bypass Surgery: A Review. Southern Medical Journal. 102:1025-1031.
-
2008The Skinny on a Growing Problem: Dry Beriberi after Bariatric Surgery. Annals of Internal Medicine. 149:842-844.